These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22023523)

  • 1. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.
    Valdez BC; Murray D; Nieto Y; Li Y; Wang G; Champlin RE; Andersson BS
    Leuk Lymphoma; 2012 May; 53(5):973-81. PubMed ID: 22023523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
    Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
    Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
    Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
    Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
    Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
    Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
    Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
    Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
    Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
    Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
    Valdez BC; Murray D; Yuan B; Nieto Y; Popat U; Andersson BS
    Oncotarget; 2022; 13():319-330. PubMed ID: 35154579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
    Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
    Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
    Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
    Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
    Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
    Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Champlin RE; Andersson BS
    Leuk Lymphoma; 2017 Nov; 58(11):2705-2716. PubMed ID: 28394191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells.
    Valdez BC; Yuan B; Murray D; Ramdial JL; Nieto Y; Popat U; Tang X; Andersson BS
    Front Oncol; 2023; 13():1287444. PubMed ID: 38074694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
    Valdez BC; Wang G; Murray D; Nieto Y; Li Y; Shah J; Turturro F; Wang M; Weber DM; Champlin RE; Qazilbash MH; Andersson BS
    Exp Hematol; 2013 Aug; 41(8):719-30. PubMed ID: 23648290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
    Teo EC; Valdez BC; Ji J; Li Y; Liu Y; Brammer JE; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Leuk Lymphoma; 2016 Nov; 57(11):2644-52. PubMed ID: 26980288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
    Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
    Valdez BC; Tang X; Li Y; Murray D; Liu Y; Popat U; Champlin RE; Andersson BS
    Exp Hematol; 2018 Nov; 67():49-59.e1. PubMed ID: 30102945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
    Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.